These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27434782)

  • 1. Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection - a long way to go.
    van Dijkman SC; Alvarez-Jimenez R; Danhof M; Della Pasqua O
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1143-56. PubMed ID: 27434782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs.
    Piana C; Antunes Nde J; Della Pasqua O
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):341-58. PubMed ID: 24460510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic considerations for anti-epileptic drugs in children.
    Verrotti A; Iapadre G; Di Donato G; Di Francesco L; Zagaroli L; Matricardi S; Belcastro V; Iezzi ML
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):199-211. PubMed ID: 30689454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy in pediatric epilepsy: rational drug and dose selection.
    Verrotti A; Piccorossi A; Lasorella S; Tambucci R
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1393-1396. PubMed ID: 27832714
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.
    Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E
    Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of oxcarbazepine: a systematic review.
    Chen YT; Wang CY; Yin YW; Li ZR; Lin WW; Zhu M; Jiao Z
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):853-864. PubMed ID: 33851561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs.
    Reife RA
    Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers in epilepsy-A modelling perspective.
    van Dijkman SC; Voskuyl RA; de Lange EC
    Eur J Pharm Sci; 2017 Nov; 109S():S47-S52. PubMed ID: 28528284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities.
    Banach M; Popławska M; Błaszczyk B; Borowicz KK; Czuczwar SJ
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1067-80. PubMed ID: 27267259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in the rational therapy of epilepsy in children (author's transl)].
    Herranz JL; Armijo JA
    An Esp Pediatr; 1978; 11(8-9):585-98. PubMed ID: 717920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for children and adolescents with epilepsy.
    Verrotti A; Loiacono G; Coppola G; Spalice A; Mohn A; Chiarelli F
    Expert Opin Pharmacother; 2011 Feb; 12(2):175-94. PubMed ID: 21208135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.
    Schulze-Bonhage A
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of treating newly diagnosed epilepsy.
    Sharma S; Kwan P
    Expert Opin Drug Saf; 2019 Apr; 18(4):273-283. PubMed ID: 30943798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiepileptic drugs--a review.
    Sankaraneni R; Lachhwani D
    Pediatr Ann; 2015 Feb; 44(2):e36-42. PubMed ID: 25658217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.
    Banach M; Borowicz KK; Czuczwar SJ
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):639-48. PubMed ID: 25740561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary efficacy of levetiracetam in children.
    Glauser TA; Dulac O
    Epileptic Disord; 2003 May; 5 Suppl 1():S45-50. PubMed ID: 12915341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations.
    Clinckers R; Smolders I; Vermoesen K; Michotte Y; Danhof M; Voskuyl R; Della Pasqua O
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1267-77. PubMed ID: 19611404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
    Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
    Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.